Physician profile
Sudeep Mohan
NPI 1225084643
$7,419.14
in general payments reported to CMS, 2019-2025
42 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $751 · 2021: $761 · 2022: $1,477 · 2023: $1,651 · 2024: $1,197 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,829 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,828.96 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,087.55 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $543.27 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $496.54 | 2019-2025 | Verquvo, Capvaxive, Januvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.30 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $467.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $461.57 | 2019-2025 | Xarelto, Spravato |
| Novo Nordisk INC | $415.30 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $412.33 | 2022-2025 | |
| Amgen INC. | $339.04 | 2019-2025 | Repatha, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $262.20 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $194.16 | 2019-2024 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $153.90 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $144.14 | 2019-2025 | Ingrezza, Ongentys |
| E.R. Squibb & Sons, L.L.C. | $142.59 | 2019-2025 | Camzyos, Eliquis |
| Axsome Therapeutics, INC. | $118.45 | 2023 | Auvelity |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $118.41 | 2021-2025 | Veozah, Myrbetriq |
| Medtronic, INC. | $117.69 | 2022-2025 | Linq II, Corevalve Evolut R, Micra |
| Edwards Lifesciences Corporation | $114.29 | 2020-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.75 | 2022-2025 | Caplyta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.80 | 2023-2025 | Lifevest |
| Corium, LLC | $96.68 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $89.80 | 2020-2022 | |
| Amarin Pharma, INC. | $88.42 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $87.78 | 2019-2023 | |
| Kestra Medical Technology Services, INC. | $76.75 | 2024-2025 | Assure Wcd |
| Kowa Pharmaceuticals America, INC. | $75.88 | 2019-2021 | |
| Abbott Laboratories | $73.46 | 2022-2025 | Freestyle Libre 3, Jot Dx |
| Exact Sciences Corporation | $59.63 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $51.53 | 2020-2021 | |
| Medtronic USA, INC. | $49.38 | 2019 | |
| Baxter Healthcare | $47.26 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Medtronic Vascular, INC. | $41.80 | 2019-2020 | |
| Glaxosmithkline, LLC. | $39.46 | 2023-2024 | Trelegy Ellipta |
| Boston Scientific Corporation | $38.05 | 2022 | |
| Daiichi Sankyo INC. | $33.71 | 2020-2022 | |
| Lundbeck LLC | $30.83 | 2019-2020 | |
| Philips North America LLC | $30.66 | 2025 | Extended Holter, Holter |
| Bardy Diagnostics, INC. | $30.18 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.81 | 2022 | |
| Eisai INC. | $20.19 | 2021 | |
| Abbvie INC. | $19.58 | 2025 | |
| Hologic Sales and Service, LLC | $18.95 | 2024 | Aptima, Thinprep 2000 Processor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudeep Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.